No abstract

Differences in molecular potency of intranasal steroids do not confer differences in efficacy.

No abstract

OBJECTIVE: We compared 220 µg daily intranasal aqueous triamcinolone acetonide (TAA AQ) with 200 µg daily fluticasone propionate (FP) for relief of seasonal allergic rhinitis symptoms. STUDY DESIGN AND SETTING: Randomized, parallel-group, investigator-blind study included patients with symptomatic seasonal allergic rhinitis. After a baseline period, TAA AQ or FP was taken for about 21 days. Nasal symptom (discharge, stuffiness, itching, sneezing) severity was recorded twice daily; total nasal symptom score was calculated. Health-related quality of life was assessed by Rhinoconjunctivitis Quality of Life Questionnaire. RESULTS: Reductions in individual symptoms and total nasal symptom score were statistically significant versus baseline and were equivalent between treatments: −3.15 ± 0.19 with TAA AQ (n = 148) and ∼3.17 ± 0.18 with FP (n = 147) (95% confidence interval for the difference, −0.7391 to 0.3693). Clinically and statistically significant improvements in Rhinoconjunctivitis Quality of Life Questionnaire scores were comparable. CONCLUSION: TAA AQ and FP were equally efficacious in relieving seasonal allergic rhinitis symptoms and improving health-related quality of life. SIGNIFICANCE: Differences in molecular potency of intranasal steroids do not confer differences in efficacy.

No abstract